Iovance Biotherapeutics is a biopharmaceutical company focused on tumor infiltrating lymphocyte (TIL) therapy, a personalized cell therapy that uses a patient's own immune cells to treat advanced solid tumors. The company operates in the fields of cell therapy, immunology, personalized medicine, and oncology, with a significant emphasis on manufacturing processes to support its treatments.
The company's primary product, Amtagvi (lifileucel), holds the distinction of being the first FDA-approved T cell therapy for a solid tumor indication. This one-time treatment involves expanding a patient's naturally occurring tumor-infiltrating lymphocytes to billions of cells before reintroduction.
Iovance Biotherapeutics maintains a substantial manufacturing presence through its 136,000-square-foot Cell Therapy Center located in Philadelphia. The organization describes itself as mission-driven with a commitment to making TIL therapy broadly accessible and advancing continuous innovation in cell therapy.
